Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Beyond Meat Inc (BYND) vs Moderna, Inc. (MRNA) Price & Performance

Beyond Meat IncTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Beyond Meat Inc vs Moderna, Inc. — how do they compare? Beyond Meat Inc trades at $0.41 (market cap $215.41M), while Moderna, Inc. trades at $63.7 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 112.3× Beyond Meat Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Beyond Meat Inc nearer its low. Which is the better fit depends on your goals.

BYNDMRNA
Market Cap
$215.41M$24.18B
Sector
Consumer StaplesHealth
52-Week High
$3.62$81.80
52-Week Low
$0.42$22.36
Enterprise Value
$455.69M$20.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Beyond Meat Inc

Beyond Meat (BYND) trades at $0.4066, down 21.81% amid a 1-for-30 reverse stock split announcement. The stock is technically bearish with negative cash flow from operations, though recent quarters show mixed earnings beats. Revenue has declined from $419M in 2022 to $275M in 2025, but net income turned positive at $178M in 2025, driven by a one-time gain. Analyst sentiment is heavily skewed toward sell ratings, reflecting skepticism about the company's turnaround efforts and persistent cash burn.

The outlook remains challenging due to declining sales, high cash burn, and weak investor confidence. While valuation ratios like P/S of 0.61 appear low, the risk of further dilution or delisting outweighs potential upside. Key risks include execution missteps and competitive pressure in the plant-based food sector.

Moderna, Inc.

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Beyond Meat Inc

Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.

Read more on BYND

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA